PMID: 11899778Mar 20, 2002Paper

Campath-1H

Clinical Journal of Oncology Nursing
P Sorokin

Abstract

Chronic lymphocytic leukemia is a malignant hemato-logical disorder characterzed by an accumulation of immunologically incompetent lymphocytes. The majority of cases (95%) are neoplasms of B-lymphocytes and 2%-5% are T-lymphocytes lymphoproliferative disorders Campath-1H (llex Pharmaceuticals, San Antonio, TX) is a humanized monoclonal antibody that is directed against CD52, a cell-surface antigen present on the lymphocytes of almost all patients with B and T cell lymphocytic leukemia. Campath-1H has shown promising results in early clinical studies, and aproval from the U.S. Food and Drug Administration for the use of this monoclonal antibody in the treatment of chronic lymphocytic leukemia may occur this year.

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Related Papers

Leukemia & Lymphoma
Adam J BassDavid A Rizzieri
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Scott J RodigJeffery L Kutok
Multiple Sclerosis : Clinical and Laboratory Research
Jennifer GravesLaura J Balcer
© 2022 Meta ULC. All rights reserved